CD274 and small cell lung carcinoma: In the recent clinical trial OAK that was conducted on 1225 patients with advanced non-squamous non-SCLC comparing atezolizumab to docetaxel revealed that the response rate to atezolizumab was better in patients whose tumors expressed higher PD-L1 levels.